IDEAYA Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 112.96 million compared to USD 58.66 million a year ago. Basic loss per share from continuing operations was USD 1.96 compared to USD 1.42 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.17 USD | +1.30% | -2.39% | +15.71% |
May. 08 | Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating | MT |
May. 07 | IDEAYA Biosciences Shares Fall After Q1 Loss | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.71% | 3.12B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- IDYA Stock
- News IDEAYA Biosciences, Inc.
- IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023